Details for Patent: 8,143,239

Which drugs does patent 8,143,239 protect, and when does it expire?

Patent 8,143,239 protects SYMBICORT and is included in one NDA.

Protection for SYMBICORT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-five patent family members in twenty-seven countries.

Summary for Patent: 8,143,239

Title:	Composition for inhalation
Abstract:	The invention relates to a formulation comprising formoterol and budesonide for use in the treatment of respiratory diseases. The composition further contains HFA 227, PVP and PEG, preferably PVP K25 and PEG 1000.
Inventor(s):	Govind; Nayna (Leicestershire, GB), Marlow; Maria (Leicestershire, GB)
Assignee:	AstraZeneca AB (Sodertalje, SE)
Application Number:	12/790,196
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,143,239
Patent Claim Types: see list of patent claims	Composition; Compound; Delivery; Use;

Drugs Protected by US Patent 8,143,239

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Astrazeneca	SYMBICORT	budesonide; formoterol fumarate dihydrate	AEROSOL, METERED;INHALATION	021929-001	Jul 21, 2006	AB	RX	Yes	Yes					Y
Astrazeneca	SYMBICORT	budesonide; formoterol fumarate dihydrate	AEROSOL, METERED;INHALATION	021929-002	Jul 21, 2006	AB	RX	Yes	Yes					Y

Foreign Priority and PCT Information for Patent: 8,143,239

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Sweden	0200312	Feb 01, 2002
Sweden	0200312	Feb 1, 2002

International Family Members for US Patent 8,143,239

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	423552
Austria	463241
Australia	2003206289
Brazil	0307193